Study objective: This study analyses for the first time endothelin-1 (ET-1) level, and gene polymorphisms for endothelin-1 (EDN1 gene) in patients with pulmonary arterial hypertension (PAH) in Egypt.
group. There was a significantly higher level of endothelin-1 in the group of pulmonary hypertension (p < 0.001). For the groups of polymorphisms studied, there was three genotypes (GT, TT, and GG), no substantial differences in genotype and allele distributions for +134 del/insA located in EDN1 gene, between PAH patients and control population, were observed (DF = 1; C.I. = 95.0; and p = 0.226). The genotype GG show the highest level of endothelin while the TT type show the lowest value of endothelin-1. Also, we found a significant relation between the higher endothelin-1 level and the lower oxygen saturation (p = 0.049), and the higher meanPAP (p = 0.004).
Conclusions: In conclusion, our findings suggest a potential link between endothelin-1 level and specific genotypes in the EDN1 gene and susceptibility for PAH with a worse haemodynamic profile. Further investigations are warranted to understand the molecular basis and to confirm the potential clinical importance of these findings on larger cohorts of patients with PAH. This will impact on the management of PAH of Egyptian patients in the near future. 
Introduction
The term pulmonary arterial hypertension (PAH) describes a rare group of diseases characterized by raised pulmonary vascular resistance, resulting from vascular remodeling in the precapillary resistance arterioles. Left untreated, patients die from right heart failure, with a mortality approaching most serious cancers. Endothelin-1(ET-1) is not only a potent vasoconstrictor, but causes proliferation of many of the vascular cells involved in vascular remodeling. Although produced mainly by the vascular endothelium, other cells such as smooth muscle, fibroblasts and macrophages are known sources of ET-1 when these cells are challenged by relevant stimuli. Plasma ET-1 levels are raised in patients with PAH and correlate with important clinical outcomes. Furthermore, ET-1 receptor antagonism has been demonstrated to improve both morbidity and mortality in conditions associated with PAH. Many articles in the literature supporting the role for ET-1 in the pathogenesis of PAH [1] .
Pulmonary arterial hypertension (PAH) is a serious disease. Its prognostic is based on the functional status quantified by the NYHA class and the 6-min walking test, and the hemodynamic data. The algorithms of treatment are solely based on the hemodynamic data and the functional status [2] .
ET-1 has an important role as vasoconstrictor and mitogen factor and its plasma levels have been found increased in PAH [3] . This molecule's effects are mediated by two receptors, ET A and ET B , found, respectively, on vascular smooth muscle and endothelial cells. They are G-protein-coupled receptors, and ET-1 vasoconstrictor effects depend on smooth muscle cell intracellular pH alkalinisation and Ca 2+ increase [4] . The two receptors have different roles: in short terms, ET A is implicated only in vasoconstriction by increasing intracellular calcium, while ET B stimulation causes first a vasodilatation, followed by vasoconstriction and has also a role in ET-1 clearance. Polymorphic changes in EDN1 (encoding for endothelin-1, ET-1) and EDNRA (encoding for endothelin receptor type A; ET-A) genes have been suggested to play a role in human heart diseases, such as hypertension and dilatated cardiomyopathy. To date, polymorphic changes in these genes have not been studied in patients with pulmonary artery hypertension (PAH) [5] [6] [7] .
Patients and methods

Subjects
All subjects or their first degree relatives did sign an informed consent for the research. Thirty patients with diagnosis of pulmonary hypertension were included in the study. Thirty control subjects were included in the study. All subjects were subjected to the following: full history taking including past history of medical diseases and drug history. Also history of diabetes mellitus (confirmed by fasting blood glucose measurement), heart failure (confirmed by echocardiography), ischemic heart diseases and arrhythmias, obstructive lung disease, interstitial lung diseases, renal, and hepatic disease were included.
Subjects were divided into two groups of matched age and sex were allocated. The first group consisted of thirty subjects, P18 years one group with no apparent evidence of disease free from pulmonary hypertension after full medical history, examination, and selected investigations (control group). The second group consisted of thirty subjects, P18 years, suffering from pulmonary hypertension. All subjects who had a documented pulmonary hypertension with routine Echodoppler study were screened for endothelin-1(ET-1) and gene polymorphism.
Definition
We defined pulmonary hypertension (PAH) by measuring mean Pulmonary Artery Pressure (mPAP) and pulmonary hypertension (PAH) was defined as an increase in the mean pulmonary arterial pressure (mPAP) to >25 mmHg at rest [8] .
Measurement of serum big endothelin-1
Measurement of serum big endothelin-1 (Big ET). Blood samples were obtained early in the morning. The big endothelin-1 levels in serum was measured by commercially available enzyme linked immunosorbent assay (ELISA) kits (Biomedica Group) [9] .
Genotyping
Genomic DNA was extracted from peripheral whole blood samples collected in tubes with EDTA. The primers that were used in PCR amplification reaction were designed with Pri-mer3 program, v.0.4.0, using genomic sequences from gene database on National Center for Biotechnology Information website, http://www.ncbi.nlm.nih.gov, (EDN1 Gene ID: 1955). We produced one amplicon for each polymorphism studied, by real time polymerase chain reaction (PCR): each reaction has a total volume of 25 ll, and was performed using 12 ng of genomic DNA, 0.5 mM dNTPs mix, 10 mM Tris-HCl pH 8.3, 50 mM KCl, 2 mM MgCl2, 2.5 pmol of each primer, 0.75 U of SYBR Green qPCR Master MixÒ (Stratagene Max 3000). Primer sequences and annealing temperature for +134 del/insA (EDN1) were forward 5 0 -CTCCTGCAGTCC-CAGCTC-3 0 , reverse 5 0 -CATGAGCAAATAATCCATTC-TG-3 0 (55°C) corresponding to a 245-bp length fragment.
Genotype/phenotype analysis and statistical methods
Descriptive statistics including frequency, distribution, mean, and standard deviation were used to describe different characteristics. Hardy-Weinberg equilibrium was calculated by chisquare test with one degree of freedom. Genotype frequencies between groups were compared by the Mann-Whitney U test or the chi square-testing, as appropriate (2 groups 
Results
Thirty patients with pulmonary hypertension 12 men (40%) and 18 female (60%) were included in the study ( Table 1 ). The mean age of the patients was 53.5 ± 12.8 years range from 34 to 72 years. The two groups of patients and control subjects were matched as regard the age and gender (Table 1 ). There were 7 (23.3%) smokers. Table 2 demonstrates the clinical data of the studied subjects which shows that COPD was the highest cause for secondary pulmonary hypertension 10 (33.3%). Most of our patients had secondary pulmonary hypertension (80%). The mean oxygen saturation was 88.76 ± 3.68%, mean pulmonary artery pressure was 55.57 ± 14.29 mmHg, Ejection Fraction (EF) was 56.03 ± 9.81%, and Fraction Shortening was 30.0 ± 5.60%.
The endothelin-1 mean was 1.8 ± 1.3 fmol/ml with range from 0.3 to 3.8 fmol/ml in the patients group. The endothelin-1 mean was 0.7 ± 0.05 fmol/ml with range from 0.6 to 0.75 fmol/ml in the patients group (Table 3 ). There was a significantly higher level of endothelin-1 in the group of pulmonary hypertension (p < 0.001). For the groups of polymorphisms studied, there was three genotypes (GT, TT, and GG), no substantial differences in genotype and allele distribu-tions for +134 del/insA located in EDN1 gene, between PAH patients and control population, were observed (DF = 1; C.I. = 95.0; and p = 0.226) ( Table 4 ). The genotype GG shows the highest level of endothelin-1 while the TT type shows the lowest value of endothelin-1 and it was statistically significant (p = 0.0001) ( Table 5 ).
We studied the correlation between the different studied parameters ( Table 6 ) and we found a significant relation between the higher endothelin-1 level and the lower oxygen saturation (p = 0.049), and the higher meanPAP (p = 0.004). Also, there was a significant correlation between lower oxygen saturation and the higher meanPAP (p = 0.011). Additionally, there was a logic significant correlation between the EF% and FS% (p = 0.0001).
The ROC curve was done to determine the best sensitivity, specificity of endothelin-1 serum level as a diagnostic tool in PH. The sensitivity of endothelin-1 was 80% and specificity was 100% in detecting PAH at a cut off value of 0.525 fmol/ml. 
Discussion
This study analyzed for the first times both serum endothelin-1 level (ET-1), and gene polymorphisms for endothelin-1 (EDN1 gene) among a sample of Egyptian patients with pulmonary arterial hypertension (PAH). The main finding of the study was the association between the endothelin-1 level and the presence of the pulmonary hypertension, as well as, the association of GG genotype with higher endothelin-1 level in PHT patients. There was a significantly higher level of endothelin-1 in the group of pulmonary hypertension (p < 0.001). For the groups of polymorphisms studied, there was three genotypes (GT, TT, and GG), no substantial differences in genotype and allele distributions for +134 del/insA located in EDN1 gene, between PAH patients and control population with a degree of freedom = 1; C.I. = 95.0; and p = 0.226. The genotype GG showed the highest level of endothelin-1 while the TT type showed the lowest value of endothelin-1. Also there was a significant relation between the higher endothelin-1 level and the lower oxygen saturation (p = 0.049), and the higher mean PAP (p = 0.004). As regards the sensitivity, specificity of endothelin-1; it was found that the sensitivity was 80% and specificity was 100% in detecting PAH at a cut off value of 0.525 fmol/ml. The pathogenesis of PAH is dominated by a significant increase of pulmonary vascular resistance, due to cellular and biochemical modifications that lead to endothelial dysfunction, vasoconstriction, arterial wall thickening and thrombosis [10, 11] . ET-1 has an important role as a vasoconstrictor and mitogen factor, and its plasma levels have been found increased in PAH [12] . ET-1 effects are mediated by two receptors, ET A and ET B , found, respectively, on vascular smooth muscle and endothelial cells [4] . In patients with moderate/severe PAH, pre-pro ET-1 mRNA levels in endothelial tissue of small arteries are significantly increased [13] . We found a significant relation between ET-1 level and severity of PAH. Previous studies on rats with PAH evidence endothelin receptor down regulation and a subsequent increase of vascular production of ET-1 and its mRNA, as well as a reduction of signal transduction [14] . Clinical investigations report an association between plasma ET-1 levels and PAH severity and outcome. All these data may suggest a key role for ET-1 and its receptors in PAH pathophysiology [15] .
ET-1 and its receptors encoding genes polymorphisms have been previously studied [10] . That study looked at two polymorphisms: the +134 ins/delA situated in 5 0 UTR of EDN1 gene and the His323His located in the sixth exon of EDNRA gene [16] . The +134 ins/delA polymorphism correlates to endothelin-1 levels in a study ex vivo performed by Popowski et al. [17] . They found that the adenine insertion is related to an increasing level of endothelin expression (measured as pre-pro-ET-1 mRNA) with an evident increase in I/I homozygous carriers (3.9-fold respect to the wild-type D/D carriers). However, our study fails to demonstrate a role of this polymorphism in patients with PAH.
However, we found that genotype GG shows the highest level of endothelin-1 while the TT type shows the lowest value of endothelin-1. That could be due to racial factor of our population which is for the first time studied for PAH and possible role of gene polymorphism and also for the small sample size and that most of (80%) our patients have a secondary PAH which is different from other study where TT genotype was the most common type for PAH as their patients had primary PAH [18] . This also, explain the lower number of TT genotype as we have only 20% of our patients with primary PAH. 
Conclusion
Our findings suggest a potential link between endothelin-1 level and specific genotypes in the EDN1 gene and susceptibility for PAH with a worse haemodynamic profile. Further investigations are warranted to understand the molecular basis and to confirm the potential clinical importance of these findings on larger cohorts of patients with PAH. This will impact on the management of PAH of Egyptian patients in the near future. Understanding the role of EDN-1 in PAH has therapeutic significance since EDN1 receptor antagonists are currently few of the best possible options available in treatment of PAH. Studies have shown that addition of sildenafil to bosentan treatment could elicit additional hemodynamic benefits in PAH patients.
Study limitations
Although our study and previous experimental and clinical studies [15, 13] suggest a potential role of endothelin-1 level and EDN1 gene polymorphisms in the pathophysiology of PAH, the main limitation of the present study is the lack of demonstration of an in vitro functional role for this genotype. Pathogenesis of PAH is incompletely characterized, but it is likely to be multifactorial, involving the interaction between the genetic milieu and the environment of the individual. Endothelin-1 and endothelin receptor gene polymorphisms are probably disease modifiers, and their interactions with other genes and environmental features should be analyzed in future investigations. Moreover, the relatively small limited cohort of patients and the inclusion of various PAH phenotypes may represent another potential bias. 
